
Misconduct and the future of neurodegenerative disease research
The Top Line
Investigating Misconduct in Alzheimer's Research
This chapter explores the investigative efforts regarding alleged misconduct linked to Cassava Sciences and its Alzheimer's drug, Simufalam. It highlights the integrity concerns that arose from the data and the broader implications for patients in clinical trials, pointing to a significant crisis in neurodegenerative disease research.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.